PharmaCyte Biotech, Inc. (PMCB)
| Market Cap | 13.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 4.50M |
| Shares Out | 7.68M |
| EPS (ttm) | 0.54 |
| PE Ratio | 3.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,894 |
| Open | 1.770 |
| Previous Close | 1.830 |
| Day's Range | 1.710 - 1.890 |
| 52-Week Range | 1.390 - 2.580 |
| Beta | -0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 13, 2024 |
About PMCB
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria ... [Read more]
Financial Performance
Financial StatementsNews
MyMD Pharmaceuticals Secures Strategic Investments
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-r...
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clin...
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedic...
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in de...
PharmaCyte Biotech Announces Final Results of Tender Offer
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,00...
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicab...
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Ce...
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box®
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.
Reiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth Waggoner's Entrenched Management Team and Unqualified, H...
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
LAS VEGAS--(BUSINESS WIRE)--Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.
IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS
NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to...
IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS
NEW YORK , July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" o...
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature liv...
IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING
Believes Truly Independent Board Required to Increase Accountability Given PharmaCyte's Long History of Missed Milestones Highlights Severe Governance Deficiencies and Recent Half-Baked Efforts to App...
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its ...
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its ...
IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS
Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations Wi...
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its...
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock.
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signa...
Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors
Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the ...